Draft Concept Paper - Development of a Stepwise Procedure for the Assessment of Substances with Endocrine Disrupting Properties According to the Plant Protection Products Regulation by German Federal Institute for Risk Assessment
 
 
 
 
 
 
 
 
Draft Concept Paper 
 
Development of a Stepwise Procedure for the Assessment 
of Substances with Endocrine Disrupting Properties  
 According to the Plant Protection Products Regulation  
(Reg. (EC) No 1107/2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
05. Mai 2010 
Seite 1 von 20 
 Bundesinstitut für Risikobewertung 
Table of contents 
 
 
Table of contents......................................................................................................................2 
 
List of abbreviations .................................................................................................................3 
 
1. Foreword ..........................................................................................................................4 
 
2. Introduction.......................................................................................................................5 
2.1. Legal background 5 
2.2. Definitions 6 
 
3. General considerations.....................................................................................................6 
 
4. Stepwise procedure for the assessment of substances with endocrine disrupting 
properties .................................................................................................................................8 
4.1. Step 1 9 
4.2. Step 2 9 
4.3. Step 3 10 
4.4. Step 4 10 
4.4.1. Option 1 10 
4.4.2. Option 2 11 
 
5. Summary ........................................................................................................................12 
 
Annex I: References...............................................................................................................14 
Annex II: Detailed draft decision tree .....................................................................................15 
Annex III: Further information on the proposed classification for ED .....................................16 
Annex IV: The OECD toolbox for testing of ED and the List of mammalian toxicology studies 
required according to Annex II to Directive 91/414/EEC ........................................................18 
Annex V: Negligible exposure ................................................................................................20 
  Seite 2 von 20 
 Bundesinstitut für Risikobewertung 
List of abbreviations 
 
ARfD  Acute Reference Dose 
BfR  Bundesinstitut für Risikobewertung (German Federal Institute for Risk As-
sessment) 
CMR  Carcinogenic, Mutagenic, or Reprotoxic 
CLP  Classifiaction, Labelling and Packaging  
DIT  Developmental Immunotoxicity 
DNT  Developmental Neurotoxicity 
EC  European Community 
ECETOC European Centre for Ecotoxicology and Toxicology of Chemicals 
ED  Endocrine Disruption / Endocrine Disruptor 
EDC  Endocrine Disrupting Chemical 
EEC  European Economic Community 
EFSA  European Food Safety Authority 
EPA  Environmental Protection Agency 
EU  European Union 
GHS  Globally Harmonised System 
HPA  Hypothalamic-Pituitary-Adrenal 
HPG  Hypothalamic-Pituitary-Gonadal 
HPT  Hypothalamic-Pituitary-Thyroid 
IPCS  International Programme on Chemical Safety 
MoA  Mechanism or Mode of Action 
MOE  Margin of Exposure 
MRL  Maximum Residue Levels 
NGO  Non-Governmental Organisation 
NOAEL No Observed Adverse Effect Level 
OECD  Organisation for Economic Co-operation and Development 
PPP  Plant Protection Product 
RE  Repeated Exposure 
REACH Registration, Evaluation, Authorisation of Chemicals 
SE  Single Exposure 
STOT  Specific Target Organ Toxicity 
TG  Testing Guideline 
TTC  Threshold of Toxicological Concern 
WHO  World Health Organization 
  Seite 3 von 20 
 Bundesinstitut für Risikobewertung 
1. Foreword 
 
Endocrine disrupting properties of natural or synthetic chemical substances have become 
subject of scientific debate and public concern during the past decades, also due to observa-
tions of environmental and adverse health effects of such substances. Since in vertebrates 
the hormonal system is involved in regulating virtually all physiological processes, there are 
multiple organ systems, tissues and endpoints which may be affected by endocrine disrup-
tion (ED). Therefore, the assessment of endocrine disrupting properties is of great impor-
tance in regulatory toxicology.  
 
In Europe, new legislation for the scientific evaluation and administrative regulation of chemi-
cal substances consequently addressing potential endocrine disrupting properties has en-
tered into force or is currently in discussion.  
 
According to the new plant protection products Regulation (EC) No 1107/2009, point 
3.6.5. of Annex II, the Commission shall present a draft of the measures concerning specific 
scientific criteria for the assessment of endocrine disrupting properties to be adopted in ac-
cordance with the regulatory procedure by 14 December 2013. Therefore, the need for the 
development of a harmonised and scientifically based guidance document is obvious. In a 
first step, according to the draft guidance on Development and Use of Guidance Documents 
(SANCO/10581/2009 REV 0) a concept paper is presented as a draft proposal. This con-
cept paper provides recommendations for the development of a guidance document on 
the assessment of active substances, safeners or synergists with potential endocrine disrupt-
ing properties in the context of Regulation (EC) No 1107/2009 concerning the placing of plant 
protection products (PPPs) on the market of the European Community. 
 
Harmonised guidance is also considered necessary for chemicals addressed under Article 
57(f) of Regulation (EC) No 1907/2006 as having endocrine disrupting properties for which 
there is scientific evidence of probable serious effects to human health which give rise to an 
equivalent level of concern to those substances meeting the criteria for classification as car-
cinogenic, as mutagenic or as toxic for reproduction category 1A or 1B in accordance with 
Regulation EC No 1272/2008. Such substances should be included into the list of sub-
stances subject to authorisation (Annex XIV). 
 
Based on the Proposal of the Commission for a Regulation of the European Parliament and 
of the Council concerning the placing on the market and use of biocidal products 
[COM(2009) 267 final from 12.6.2009] the same measures addressed under Article 57(f) of 
Regulation (EC) No 1907/2006 concerning specific scientific criteria for the assessment of 
endocrine disrupting properties should be applied as cut off criteria for the approval of bio-
cidal active substances and their products.  
 
As an important goal for the development of a new guidance on measures concerning spe-
cific scientific criteria for the assessment of substances with endocrine disrupting properties 
considering human relevance it is regarded necessary that they should be applicable under 
the different areas of EC legislation (chemicals under REACh as well as active substances 
in pesticides and biocides) taking into account specific aspects within the different areas, as 
appropriate.  
 
As a result of an international workshop, held in Berlin 2009, a draft concept paper was pro-
vided by the BfR as a first input for the development of a harmonised European guidance 
document for use by Member State authorities and EC peer review groups and to assist 
Member States, EFSA and the European Commission when making decisions about the 
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approval of active substances, safeners or synergists with endocrine disrupting properties in 
accordance with point 3.6.5. of Annex II to Regulation (EC) No 1107/2009. It should also 
provide applicants with advice on the drafting of a dossier with a scientifically reasoned pro-
posal for the assessment and classification of substances considered to have endocrine dis-
rupting properties. This dossier should enable the Member States to evaluate an application 
for authorisation without the need to refer back to the applicant except for occasional clarifi-
cation or further information, thus improving the efficiency and cost-effectiveness of the au-
thorisation process. 
 
 
2. Introduction 
2.1. Legal background 
 
Regulation (EC) No 1107/2009 concerning the placing of plant protection products (PPPs) on 
the market states in Article 4 (1) that the assessment of the active substance shall first estab-
lish whether the approval criteria set out in points 3.6.2 to 3.6.4 and 3.7 of Annex II are satis-
fied.  
In the context of this concept paper, only the approval criteria set out in point 3.6 of Annex II 
(impact on human health) will be considered, whereas approval criteria relating to ecotoxi-
cology (i.e. point 3.8.2. of Annex II; endocrine disrupting properties that may cause adverse 
effects on non-target organisms) are not taken into consideration. 
 
The approval criteria which shall be taken into consideration first in the assessment of a sub-
stance (points 3.6.2 to 3.6.4 of Annex II) are as follows: 
 
 “3.6.2. An active substance, safener or synergist shall only be approved if … it is not 
or has not to be classified … as mutagen category 1A or 1B.” 
 
 “3.6.3. An active substance, safener or synergist shall only be approved if … it is not 
or has not to be classified … as carcinogen category 1A or 1B, unless the exposure 
of humans … is negligible ...” 
 
 “3.6.4. An active substance, safener or synergist shall only be approved if … it is not 
or has not to be classified … as toxic for reproduction category 1A or 1B, unless the 
exposure of humans … is negligible …” 
 
If the approval criteria mentioned above are satisfied, then the approval criteria set out in 
point 3.6.5 of Annex II shall be considered: 
 
 “3.6.5. An active substance, safener or synergist shall only be approved if, on the ba-
sis of the assessment of Community or internationally agreed test guidelines or other 
available data and information, including a review of the scientific literature, reviewed 
by the Authority, it is not considered to have endocrine disrupting properties that may 
cause adverse effect in humans, unless the exposure of humans to that active sub-
stance, safener or synergist in a plant protection product, under realistic proposed 
conditions of use, is negligible, that is, the product is used in closed systems or in 
other conditions excluding contact with humans and where residues of the active 
substance, safener or synergist concerned on food and feed do not exceed the de-
fault value set in accordance with point (b) of Article 18(1) of Regulation (EC) No 
396/2005. 
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By 14 December 2013, the Commission shall present to the Standing Committee on 
the Food Chain and Animal Health a draft of the measures concerning specific scien-
tific criteria for the assessment of endocrine disrupting properties to be adopted in ac-
cordance with the regulatory procedure with scrutiny referred to in Article 79(4). 
Pending the adoption of these criteria, substances that are or have to be classified, in 
accordance with the provisions of Regulation (EC) No 1272/2008, as carcinogenic 
category 2 and toxic for reproduction category 2, shall be considered to have endo-
crine disrupting properties. 
In addition, substances such as those that are or have to be classified, in accordance 
with the provisions of Regulation (EC) No 1272/2008, as toxic for reproduction cate-
gory 2 and which have toxic effects on the endocrine organs, may be considered to 
have such endocrine disrupting properties.” 
 
2.2. Definitions 
 
It is proposed that, in the context of this concept paper for the development of specific scien-
tific criteria for the assessment of substances with endocrine disrupting properties consider-
ing human relevance,  
 
1. the (WHO/IPCS 2002) definition of the term “endocrine disruptor” should be used:  
 
 Endocrine Disruptor (ED): “An ED is an exogenous substance or mixture that alters 
function(s) of the endocrine system and consequently causes adverse health effects 
in an intact organism, or its progeny, or (sub) populations.” (WHO/IPCS 2002) 
 
2. the (WHO/IPCS 2004) definition of the term “adversity” (extended by the addition of 
the term “reproduction”) should be used:  
 
 Adversity: “A change in morphology, physiology, growth, [reproduction], develop-
ment or lifespan of an organism which results in impairment of functional capacity or 
impairment of capacity to compensate for additional stress or increased susceptibility 
to the harmful effects of other environmental influences.” (WHO/IPCS 2004) 
 
3. suggestions for a draft definition for negligible exposure for further discussion are 
provided in annex V. 
 
Further definitions needs to be discussed and harmonised (e.g. serious effects to human 
health) in the context of the development of guidance documents for chemicals and active 
substances in biocidal products addressed under Article 57(f) of Regulation (EC) No 
1907/2006.   
 
 
3. General considerations 
 
The aim of this chapter is to provide a general reference to the stepwise approach of hazard 
assessment for an active substance, safener or synergist in PPP or biocidal products. Fun-
damental steps for scientific criteria in hazard assessment are based on the following princi-
pal steps: 
 
 description of the toxicological profile of the substance; 
 identification of the relevant critical effects in the most relevant and sensitive species;  
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 dose-response evaluation, i.e. identification of the LOAEL (lowest-observed-adverse-
effect level) and the NOAEL (no-observed-adverse-effect level) for the critical effects; 
 establishment of a mechanism/mode of action, if possible. 
 
For the inclusion of an active substance in Annex I and for an application for the authorisa-
tion of a PPP, a comprehensive range of toxicological and toxicokinetic data must be as-
sessed. The information for the chemical substance1, taken together with that provided for 
one or more preparations containing the substance, must be sufficient to permit an evalua-
tion to be made as to the risks for humans, associated with the handling and use of PPPs 
containing the active substance. These data requirements and test methods for the approval 
of a PPP are specified by Directive 94/79/EC amending Directive 91/414/EEC (see Table 1 
in Annex IV). 
 
It is recognised that endocrine modulation is not a hazard per se, but a mechanism/mode of 
action (MOA) of toxicity that may cause adverse effect in humans. Since all endocrine disrup-
tors do not represent the same hazard to humans, a) an evaluation of the mechanism/mode 
of action (MOA) and its relevance for humans and b) an element or assessment of potency is 
also required to discriminate endocrine disruptors of high concern from those of lower con-
cern. 
 
Essentially, all mammalian toxicity and toxicokinetic studies required under Directive 
91/414/EEC2 (Annex IV) should be considered when assessing a chemical substance with 
endocrine disrupting properties potentially relevant to humans. Provided that other reliable 
relevant data are available, e. g. from peer-reviewed scientific literature, these should also be 
considered in the assessment process. In the case of suspected endocrine disruption, addi-
tional mechanistic data may be required to establish or support a certain mechanism/mode of 
action (MOA). A thorough investigation of the MOA for toxicity can help in the assessment of 
qualitative or quantitative differences between species. 
 
In addition to the toxicity data chemical characterisation is regarded important to provide in-
sights to key questions, including compounds stability, the potential for human exposure or 
the potential for accumulation. 
 
Furthermore the OECD has developed a framework for testing and assessment of endocrine 
disrupting chemicals (OECD 2002). This approach, however, represents a toolbox and not a 
tiered approach for decision making (Annex IV). It is noted that highest tier tests are already 
included in the data requirements for plant protection products.  
 
The required studies are expected to be able to provide evidence for endocrine effects. 
These include the recently amended short-term toxicity studies, the chronic toxic-
ity/carcinogenicity studies, the (two-generation) reproduction studies, and the prenatal devel-
opmental toxicity studies. The latter studies are able to integrate the form and function of 
multiple biological processes, including those endpoints that are especially vulnerable to en-
docrine modulation. For the testing and assessment of potential endocrine disrupting chemi-
cals, these so called apical in vivo assays (ECETOC 2009) can therefore provide the most 
relevant data about multiple endocrine mechanisms and effects i.e. they represent the cur-
rent highest tier tests for detecting endocrine disrupting properties in mammals. It is a distinct 
                                                
1 In this paper an active substance, safener or synergist in a plant protection product 
2 Since the new European plant protection product regulation (Regulation (EC) No 1107/2009), replacing Directive 91/414/EEC, 
states that modified data requirements will be provided by June 2011, the old list remains valid until replaced.  
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advantage that studies of this type are usually available at the beginning of the hazard identi-
fication in cases of pesticide and biocide human health evaluation. 
 
For certain chemical substances, there is some evidence that effects may not follow a mono-
tonic dose response curve, potentially occurring at very low doses. Also, there is concern 
expressed by several scientists that endocrine disrupting effects might be overlooked in cur-
rent guideline-conform toxicity testing. Therefore, triggered by evidence (provided that so-
called low dose effects are further substantiated concerning robustness and reproducibility), 
improvement of testing methods with regard to the low dose range should be considered on 
a case-by-case basis, in order not to dismiss effects on the endocrine system which might be 
of relevance to human health. 
 
 
4. Stepwise procedure for the assessment of substances with endocrine 
disrupting properties  
 
For the assessment of substances with endocrine disrupting properties that may cause ad-
verse health effects in humans, a stepwise procedure is proposed to support a science 
based regulatory decision process (Fig. 1). This stepwise approach (also referred to as 
‘tiered approach’) is based on the recommendations of an international expert workshop, 
hosted by the BfR in Berlin 2009 (BfR 2010). In addition, it is proposed to establish criteria for 
classification of endocrine disruptors based on Regulation (EC) No. 1272/2008 (European 
Council 2008).  
 
A stepwise approach is suggested that is based on specific scientific criteria established for 
substances with potential endocrine disrupting properties in plant protection products. These 
proposed criteria have been integrated into a decision tree (Annex 2). An important feature of 
the stepwise approach is the ability to exit the approach at any point when sufficient data 
have been evaluated for decision making. Within the proposed procedure science-based 
parameters such as adversity, biological or human relevance are used to analyze potential 
endocrine disrupting properties. For decision making in the final step of the tiered approach 
two options are suggested: An exposure-based option, taking into account (negligible) expo-
sure and a classification-based option making use of classification and labelling according to 
criteria laid down under Regulation (EC) No. 1272/2008 and respective guidance documents.  
 
It is recommended that the proposed measures should be tested upon a certain number of 
plant protection products to examine their applicability and to facilitate improvement of the 
framework. 
 
In any case, the decision should be made on a case-by-case basis and must be based on 
expert judgement.  
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I. Evaluation of all available data / relevant endpoints 
(endpoint-based) 
II. Analysis of endocrine disruption in animals 
(mechanism-based) 
IV. Options for a regulatory decision   
(exposure-based or classification-based) 
 
 III. Analysis of relevance for humans 
(default assumption: relevance) 
 
 
Figure 1: Conceptual framework for a tiered / stepwise approach for decision making. This 
tiered approach represents an overview and reflects the way a regulatory decision process 
may be made in general. A more detailed decision tree is shown in Annex 2. For the decision 
in step IV two options are suggested: Option 1 is exposure-based while option 2 is classifica-
tion-based. A detailed description of these options is given in the text. 
 
4.1. Step 1 
In a first step, the proposal stipulates the chemical characterisation and an comprehensive 
analysis of all available toxicological data as a starting point for the decision process. These 
toxicity data required in a regulatory context as well as all other available data (including data 
from peer-reviewed scientific journals) should be analysed for potential hazards. Based on 
hazards identified by analysis of the respective toxicological endpoints, classification and 
labelling of the substance in accordance with Regulation (EC) No 1272/2008 (European 
Council 2008) can be proposed. Substances which would have to be labelled as carcino-
genic, mutagenic or as reprotoxic (CMR) categories 1A and 1B would not be included into 
Annex I as requested by Regulation (EC) No. 1107/2009. Since the decision process on 
classification and labelling is not yet completed at this step, it is recommended to also in-
clude substances proposed to be labelled CMR 1A or 1B into the analysis of endocrine dis-
rupting properties, and to clarify their mechanism of toxicity.  
 
4.2. Step 2 
In a second step, this endpoint-based analysis would be translated into a mechanism-based 
analysis. At this stage it is proposed to analyse all available data for effects / endpoints po-
tentially caused by an endocrine disruptor, hence to analyse the potential endocrine mecha-
nism(s) of the respective substance. Since hormonal regulation is involved in virtually all 
physiological processes of animals, it is crucially important at this stage to have criteria at 
hand to distinguish between physiological and adverse hormonal effects.  
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Several other potential criteria can be suggested for the evaluation of such harmful endocrine 
disrupting effects (Marx-Stoelting et al. 2009). Among these are adversity, specificity, dose-
dependency as well as human relevance. Adversity in combination with toxicological rele-
vance is considered the most important criterion for decision on ED for regulation at this 
stage. Adversity should be understood as defined above.  
 
If there is no evidence for adverse / toxicologically relevant effects potentially related to ED, 
the decision tree can be left at this step. If on the other hand effects potentially related to an 
endocrine disruptive mechanism occur, which are regarded as adverse, it will be necessary 
to establish a mode of action in animals. One possibility for doing this might be the adoption 
of the IPCS conceptual framework, originally developed for evaluation animal carcinogene-
sis, for the assessment of the MOA of endocrine disrupting properties (Boobis et al 2006, 
2008). For this purpose, additional mechanistic studies in vivo and in vitro may be necessary. 
The default assumption at this stage is that the mechanism is endocrine. If no mechanistic 
data are provided or if the mechanism of toxicity is shown to be endocrine, the substance 
may be considered as being an endocrine disruptor in animals. However, if the mechanistic 
data clearly show that the mechanism of toxicity is not based on endocrine effects, the sub-
stance is presumably not an endocrine disruptor and the decision tree can be left at this step. 
 
4.3. Step 3 
In a third step, relevance of effects observed in animal studies for humans will have to be 
analysed. The default assumption at this stage would be relevance. Consequently, only if a 
mechanism of toxicity in animals is identified that is clearly not relevant to humans, the deci-
sion tree might be left at this step.  
If possible, detailed information on individual mechanisms of action should be established at 
this stage. Frameworks such as the IPCS frameworks for analysing the relevance of a can-
cer as well as a non-cancer mode of action for humans (Boobis et al. 2006, 2008) or other 
human relevance frameworks could be integrated into the decision process.  
 
4.4. Step 4 
The fourth step consists of the decision whether a substance would have to be regarded as 
an endocrine disruptor in a regulatory sense, i.e. whether it is considered to have endocrine 
disrupting properties that may cause adverse effect in humans or not. At this stage the final 
decision on approval or disapproval should be made, based on a critical assessment of ex-
posure (option 1) or classification of the respective substance for ED properties (option 2).  
 
As a more detailed elaboration of this stepwise approach a draft decision tree is presented in 
Figure 2 in the Annex. 
4.4.1. Option 1 
This exposure-based option foresees that an exposure analysis is performed to find out 
whether or not exposure to the respective substance for consumers as well as for operators, 
workers and others who might be exposed to the substance is negligible. This option empha-
sizes the generation and use of sufficient exposure data where possible for decision making 
and encourages the collection of appropriate exposure data. Approval of a substance with 
human relevant endocrine disrupting properties would only be possible if the exposure of 
humans under realistic proposed conditions of use is negligible as defined by Regulation 
(EC) No 1107/2009 in Annex II point 3.6.5.  
 
A more science-based definition of negligible exposure is suggested in Annex V.  
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4.4.2. Option 2 
This classification-based option for decision making suggests to amend criteria for classifica-
tion and labelling and to introduce a classification system for endocrine disruptors for which 
there is scientific evidence of probable serious effects to human health which give rise to an 
equivalent level of concern to those substances meeting the criteria for classification as car-
cinogenic, as mutagenic or as toxic for reproduction category 1a or 1b in accordance with 
Reg. (EC) No. 1272/2008. A decision on approval or disapproval could then be based on the 
hazard identified and the classification applied for a respective substance. Endocrine disrupt-
ing properties would be treated like CMR-properties, for which a classification-based cut-off 
for substances classified as CMR 1A or 1B has been implemented in the new plant protec-
tion products regulation.   
 
General considerations 
It is proposed that for the assessment of substances which have endocrine disrupting proper-
ties in mammals, the principles for hazard classification and labelling as laid down in Regula-
tion (EC) No 1272/2008 might be considered. However, this regulation does not provide spe-
cific criteria for the classification of potential health hazards of substances with endocrine 
disrupting properties in mammals. Therefore it is proposed to adjust the basic classifica-
tion criteria appropriately taking into consideration the specific end-points which may be 
adversely affected by endocrine disruptors.  
 
Substances with endocrine disrupting properties in mammals shall be classified as “endo-
crine disruptor (ED)” by the use of expert judgement, on the basis of the weight of all evi-
dence available, including the use of recommended guidance values which take into account 
the duration of exposure and the dose/concentration which produced the effect(s), and are 
placed in one of two categories, depending upon the nature and severity of the effect(s) ob-
served. In this context it should be mentioned that for ED one effect may trigger more than 
one classification and labelling (e.g. C and / or R and ED). 
 
Category 1 
Substances are classified in Category 1 for “endocrine disruptor” on the basis of reliable and 
good quality evidence from human cases or epidemiological studies or observations from 
appropriate studies in experimental animals in which severe toxic effects on the endocrine 
system, assumed to be of relevance to human health, were produced at generally low expo-
sure concentrations. Guidance on evaluation of effects and guidance dose values are based 
on those suggested for specific target organ toxicity after repeated exposure (STOT-RE) in 
Reg. (EC) No. 1272/2008 are provided in Annex III, to be used as part of a weight-of-
evidence evaluation. 
 
Category 2 
Substances are classified in Category 2 for “endocrine disruptor (ED)” on the basis of obser-
vations from appropriate studies in experimental animals in which significant toxic effects 
on the endocrine system, assumed to be of relevance to human health, were produced at 
generally moderate exposure concentrations. Guidance on evaluation of effects and guid-
ance dose values are based on those suggested for specific target organ toxicity after re-
peated exposure (STOT-RE) in Reg. (EC) No. 1272/2008 are provided in Annex III, to be 
used as part of a weight-of-evidence evaluation. 
 
As a general rule, for the assessment and classification of substances with endocrine dis-
rupting properties potentially relevant to humans, data from animal studies in mammals 
should have precedence over data from in vivo studies in non-mammalian species. 
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At present, data from most available in vitro test methods is not considered of sufficient 
weight of evidence on its own for regulatory decisions such as classification and labelling. 
However, such data may be helpful in the assessment of adverse effects on the endocrine 
system, for instance to clarify the mechanism/mode of action (MOA) and its relevance for 
humans. The quality of these studies and the adequacy of the data provided should be care-
fully evaluated on a case-by-case basis. 
 
 
Approval of substances with endocrine disrupting properties based on the adjustment 
of the basic classification criteria according to CLP 
 
It is proposed that an active substance, safener or synergist shall only be approved if, on the 
basis of assessment of endocrine disrupting toxicity testing carried out in accordance with 
the data requirements for active substances, safeners or synergists and other available data 
and information, including a review of the scientific literature, it is not or has not to be classi-
fied, in accordance with the provisions of Regulation (EC) No 1272/2008, as Endocrine Dis-
ruptor (ED) category 1, unless the exposure of humans to that active substance, safener or 
synergist in a plant protection product, under realistic proposed conditions of use, is negligi-
ble, that is, the product is used in closed systems or in other conditions excluding contact 
with humans and where residues of the active substance, safener or synergist concerned on 
food and feed do not exceed the default value set in accordance with point (b) of Article 18(1) 
of Regulation (EC) No 396/2005. 
 
Substances that are or have to be classified, in accordance with the provisions of Regulation 
(EC) No 1272/2008, as Endocrine Disruptor (ED) category 2 shall not fall under the cut-off 
and go to regular risk assessment. Regular risk assessment is also foreseen to be conducted 
for substances with any combination of category 2 classifications for respective endpoints 
(like C, M or R cat. 2).  
 
 
5. Summary 
 
This concept paper for a guidance document provides a first draft based on the outcome of a 
BfR workshop3 on how evaluation of endocrine effects of active substances, safeners or syn-
ergists to be used in plant protection products might be conducted. Its development has be-
come necessary in the context of Regulation (EC) No 1107/2009 concerning the placing of 
plant protection products on the market of the European Community. Even though the criteria 
developed and the data set used as a basis for toxicological analysis of such substances are 
considered to be specific for plant protection products, it is recognized that a guidance 
document once developed might also have implications for other classes of substances such 
as biocides or chemicals under REACh. It is recommended that the proposed measures 
should be tested upon a certain number of plant protection products to examine their appli-
cability and to facilitate improvement of the framework. 
 
Concerning specific scientific criteria for the assessment of endocrine disrupting properties, a 
tiered approach for decision making is proposed reflecting single steps of the regulatory de-
cision process on substances with endocrine disrupting properties for their use in plant pro-
tection products. In a first step all available data are evaluated in an endpoint-based manner. 
In a second step mechanisms of toxicity are analysed if present. Human relevance of these 
                                                
3http://www.bfr.bund.de/cm/218/establishment_of_assessment_and_decision_criteria_in_human_health_risk_assessment_for_
substances_with_endocrine_disrupting_properties.pdf 
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mechanisms of toxicity is examined in a third step. The fourth step consists of a decision. In 
this context two options are proposed which may be regarded as alternatives, representing to 
some extent complementary procedures:  
 
Option 1: An exposure-based approach is suggested, that foresees exposure analysis and 
a decision based on the question whether or not exposure to an ED is negligible. 
 
Option 2: In a classification-based manner it is alternatively proposed to adjust the current 
classification criteria laid down in Regulation (EC) No. 1272/2008 for substances with endo-
crine disrupting properties. As a next step, it is suggested to classify substances with endo-
crine disrupting properties based on the regulatory framework for specific target organ toxic-
ity as endocrine disruptors (ED). While substances that have to be labelled ED category 1 
would fall under the cut-off criterion, substances labelled ED 2 would not. 
 
As a more detailed elaboration of this stepwise approach a draft decision tree is provided 
including specific criteria such as adversity or biological relevance. Definitions for ED and 
adversity used in this context are considered to be based on current WHO/IPCS recommen-
dations. 
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Annex II: Detailed draft decision tree 
 
Evidence for adverse / toxi-
cologically relevant effects 
potentially related to ED? 
NO
Cancer  
EffectsA
 Reprotoxic 
EffectsA
 Spec. Target 
Organ Tox.B
 
No ED
Relevance of mechanism or mode of 
action to humans?D
 No human 
relevant 
ED
NO
Additional Mecha-
nistic studies
Mechanism related to ED? NO No ED
Sufficient information to 
Establish MoA in animalsC 
YES
YES
YES
Evaluation of all available data 
Option 1: Exposure-based decision  
Option 2: Classification-based decision   
 
Figure 2: Detailed draft decision tree. Colours of boxes represent the relation to the four 
steps of the stepwise approach shown in Figure 1. After evaluation of all data an endpoint 
based hazard analysis is conducted (grey boxes). This is followed by an analysis of the 
mechanisms, which might have caused toxicity (green boxes). This mechanistic evaluation 
includes criteria like adversity as well as the establishment of a mode/mechanism of action in 
animals. If this mechanism is related to ED, its relevance to humans will be analysed with the 
default assumption being relevance to humans (blue box). After comparison to exposure a 
decision is made on ED in the last step (red box, option 1). Alternatively this decision might 
be based on classification (option 2).  
A: Category 1A and 1B carcinogens and / or reprotoxicants are foreseen to be automatically 
banned at this stage. To clarify the mechanism of toxicity it is recommended to also analyse 
these substances for endocrine disrupting properties. B: Specific target organ toxicity (STOT) 
is a possible label for toxicity to any organ. In the context of endocrine disruption, not only 
effects on organs of the endocrine system, but also effects on the immune- or the nervous-
system may be regarded as being of particular importance. C: Establishing of a mechanism 
or mode of action at this stage could consist of individual steps as suggested by the IPCS 
MOA framework. D: Relevance to humans could be assessed according to the IPCS MOA 
framework at this stage by analysing potential qualitative and quantitative relevance to hu-
mans separately. 
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Annex III: Further information on the proposed classification for ED 
 
1. Effects considered to support classification for ED  
 
For active substances, safeners or synergists used in plant protection products, the most 
relevant apical toxicology test methods for detecting substances which have endocrine dis-
rupting properties in mammals are the short-term toxicity studies, the chronic toxic-
ity/carcinogenicity studies, the (two-generation) reproduction studies, and the prenatal devel-
opmental toxicity studies. 
 
Evaluation of data from these studies in experimental animals and of the available data from 
human experience/incidents is necessary to assess whether a consistent and significant 
toxic effect supports a classification for endocrine disrupting properties. Thus, all available 
evidence on the relevance to human health shall be taken into consideration in the assess-
ment and classification process, including but not limited to the following toxic effects in hu-
mans and/or animals: 
 significant functional changes in the endocrine system or hormone-dependent or-
gans/tissues; 
 any consistent and significant adverse change in clinical biochemistry, haematology, 
or urinalysis parameters, only if related to endocrine disruption; 
 significant organ damage noted at necropsy and/or subsequently seen or confirmed 
at microscopic examination, only if related to endocrine disruption; 
 morphological changes that are potentially reversible but provide clear evidence of 
marked organ dysfunction, only if related to endocrine disruption. 
 
For the assessment of human relevance of a toxic effects observed in experimental animals, 
the IPCS framework for analyzing the relevance of a cancer as well as a non-cancer mode of 
action (MOA) for humans (Boobis et al. 2006, 2008) or any other feasible human relevance 
framework may be considered. The first step in this framework is to determine whether the 
weight of evidence based on experimental observations is sufficient to establish a hypothe-
sized MOA. This comprises a series of key events causally related to the toxic effect. These 
events are then compared qualitatively and, next, quantitatively between experimental ani-
mals and humans. 
 
 
2. Effects considered not to support classification for ED  
 
It is recognised that effects may be seen in humans and/or in studies in experimental animals 
that do not justify classification. Such effects include, but are not limited to: 
 clinical observations or small changes in bodyweight gain, food consumption or water 
intake that may have toxicological importance but that do not, by themselves, indicate 
significant toxicity; 
 small changes in clinical biochemistry, haematology or urinalysis parameters and/or 
transient effects, when such changes or effects are of doubtful or minimal toxicologi-
cal importance; 
 changes in organ weights alone with no evidence of organ dysfunction; 
 adaptive responses that are not considered toxicologically relevant unless they lead 
to endocrine disruption; 
 substance-induced species-specific mechanisms of toxicity, i.e. demonstrated with 
reasonable certainty to be not relevant for human health, shall not justify classifica-
tion. 
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3.     Guidance values to assist with classification for ED  
 
In toxicity studies conducted in experimental animals, reliance on observation of effects 
alone, without reference to the duration of exposure and dose, violates a fundamental con-
cept of toxicology, i.e. all substances are potentially toxic, and the toxicity is determined by 
the dose and the duration of exposure. 
 
In order to help reach a decision about whether a substance shall be classified or not, and to 
what degree it shall be classified (Category 1 or Category 2), guidance values are provided 
for consideration of the dose which has been shown to produce significant toxic effects. The 
principal argument for proposing such guidance values is that all substances are potentially 
toxic and there has to be a reasonable dose above which a degree of toxic effect is acknowl-
edged. It is therefore to be considered not only which effects have been produced, but also 
at which dose they occurred and how relevant they may be for humans. 
 
Thus, when significant toxic effects are observed in animal studies that might warrant classi-
fication, the duration of exposure and the dose at which these effects were seen, in relation 
to the suggested guidance values, should be considered. Also, the decision to classify at all 
can be influenced by reference to the dose guidance values at or below which a significant 
toxic effect has been observed. 
 
The guidance values proposed in Table 2 refer to significant toxic effects seen in a standard 
90-day study. They can be used as a basis to extrapolate equivalent guidance values for 
toxicity studies of longer or less duration. The assessment shall be done on a case-by-case 
basis; for a 28-day study the guidance values are increased by a factor of three, and for a 
chronic toxicity study the guidance values are decreased by a factor of two. The values pro-
posed in Table 2 are intended only for guidance purposes, i.e. to be used as part of the 
weight of evidence approach, and to assist with decisions about classification. They are not 
intended to be regarded as strict demarcation values. 
 
Table 2. Guidance values for classification ED (in mg/kg bw per day). 
 
Study type ED 1 ED 2 
28-day oral toxicity ≤ 30 ≤ 300 
90-day oral toxicity ≤ 10 ≤ 100 
Chronic toxicity ≤ 5 ≤ 50 
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Annex IV: The OECD toolbox4 for testing of ED and the list of mammalian toxi-
cology studies required according to Annex II to Directive 91/414/EEC 
 
 
                                                
4 Adapted from http://www.oecd.org/document/58/0,3343,en_2649_34377_2348794_1_1_1_1,00.html  
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Table 1. List of mammalian toxicology studies required according to Annex II to Directive 91/414/EEC. The 
listed studies should be conducted in accordance with international guidelines such as OECD guidelines.  
 
Area of toxicology Specific studies Annex Point 
5.1./5.1.1. Absorption, distribution and excretion – following single and 
repeated oral administration 
Toxicokinetic studies 
Metabolism 5.1.2. 
5.2./5.2.1. Oral 
5.2.2. Percutaneous 
5.2.3. Inhalation 
5.2.4./5.2.5. Skin and eye irritation 
Acute toxicity 
Skin sensitisation 5.2.6. 
5.3./5.3.1. Oral cumulative toxicity (28 day) 
5.3.2. Oral administration – two species, one rodent (preferably 
rat) and one non-rodent, usually 90-day study 
Short term toxicity5 
Other routes if appropriate 5.3.3. 
5.4. Mutagenicity Test battery to assess gene mutations, chromosomal aberra-
tions and DNA perturbations 
5.5. Long term toxicity and 
carcinogenicity 
Oral long term toxicity and carcino-genicity (rat and other 
mammalian species) – other routes as appropriate 
5.6./5.6.1. Multi-generation studies Reproductive toxicity 
Developmental toxicity studies 5.6.2. 
5.7./5.7.1 Neurotoxicity studies in rodents Neurotoxicity studies 
Delayed polyneuropathy studies 5.7.2. 
5.8./5.8.1. Toxicity studies of metabolites as referred to in the introduction Other toxicological 
studies6 Supplementary studies on the active substance 5.8.2. 
5.9./5.9.1.-5.9.8. Medical data Medical surveillance on manufacturing plant personnel; direct 
observations (e.g. clinical cases and poisoning incidences); 
health records from industry and agriculture; epidemiological 
studies; diagnosis of poisoning; allergenicity observations; 
proposed treatment and prognosis of expected effects of poi-
soning 
5.10 Summary of mammalian toxicity and overall evaluation 
 
                                                
5 Target organs, where relevant (especially immune, nervous and endocrine systems; if nervous system, immune system or 
endocrine system are specific targets in short term studies at dose levels not producing marked toxicity, additional second tier 
tests including functional testing should be considered). 
6 In certain cases it can be necessary to carry out supplementary studies to clarify observed effects further. These studies could 
include studies on potential effects on the endocrine system. 
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Annex V: Negligible exposure 
 
 Exposure of „workers, consumers and bystanders“ to the active substance of a 
biocidal product is considered negligible with respect to ED if 
a.) total systemic exposure or local exposure counts for less than 10% of the cor-
responding reference value (AEL) or 
b.) the active substance is not genotoxic and the total internal exposure to the ac-
tive substance does not exceed 1.5 µg per person and day. 
 
Explanation 
a.) The definition of negligible exposure as percentage of a reference value is the 
most transparent and verifiable option. A general margin of 1000 to the lowest 
NOAEL (assuming a general assessment factor of 100) is considered safe. The 
percentage value of 10% is sufficiently low to leave room for any additional expo-
sure from unknown sources. This definition also prevents the inclusion of sub-
stances for which a threshold value cannot be set (e.g. most genotoxic carcino-
gens).  
b.) The value of 1.5 µg/person/d is derived from a statistical evaluation of chronic 
studies by Munro et al. (1996) for more than 600 substances. Below this amount 
the risk to human health from any substance (except genotoxic carcinogens) is 
considered negligible. If this criterion should be applied, it is considered neces-
sary to prove by appropriate tests, preferably in vitro, that the substance is not 
genotoxic. 
 
 
